[{"edinetCode":"E00978","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":367.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":16387000.0,"sharesOwendPercent":0.6288,"outstandingShares":null,"numberOfSubsidiary":6.0,"bps":269.45,"equityRatio":0.677,"cashAndCashEquivalents":2495980000.0,"assets":10296725000.0,"currentAssets":6162295000.0,"fixedAsset":4134429000.0,"tangibleFixedAssets":2381933000.0,"intangibleFixedAssets":112833000.0,"investmentAndOtherAssets":1639663000.0,"liabilities":3330198000.0,"currentLiabilities":2161396000.0,"shorTermDept":1047634000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1168802000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1136497000.0,"netAsset":6966527000.0,"capitalStock":6939471000.0,"capital":4482936000.0,"capitalSurplus":4198562000.0,"accumulatedEarnings":-1698272000.0,"treasuryStock":-43754000.0,"valuationAndConversionAdjustments":27056000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":7348908000.0,"costOfSales":3120583000.0,"grossProfit":4228324000.0,"sgaExpenses":4143195000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1289551000.0,"operatingIncome":85129000.0,"nonOperatingIncome":56951000.0,"nonOperatingExpenses":77399000.0,"interestExpense":26964000.0,"ordinaryProfit":64681000.0,"extraordinaryGain":336485000.0,"extraordinaryLoss":174587000.0,"incomeBeforeTax":226578000.0,"incomeTaxes":37483000.0,"netIncome":189094000.0,"netIncomeAttributableToOwnersOfTheParentCompany":188744000.0,"comprehensiveIncome":118863000.0,"eps":7.3,"dilutedEps":null,"dividendPerShare":null,"per":70.3,"roe":0.027,"cashFlowFromOperatingActivities":833670000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-363923000.0,"cashFlowFromFinancialActivities":-883499000.0,"changesInCashAndCashEquivalents":-461982000.0,"列1":"asr","submitDate":"2017\/6\/23","stockCode":4557,"accountingYear":"第48期（自　平成28年４月１日　至　平成29年３月31日）","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00978","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4482,"settlementDate":"2022\/3\/31","submitterName":"株式会社医学生物学研究所","submitterNameEnglish":"MEDICAL&BIOLOGICAL LABORATORIES CO., LTD.","submitterNameKana":"カブシキガイシャイガクセイブツガクケンキュウショ","location":"名古屋市中区栄四丁目５番３号","industory":"医薬品","corporateNumber":7180000000000.0},{"edinetCode":"E00978","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":406.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3311000.0,"sharesOwendPercent":0.6403,"outstandingShares":null,"numberOfSubsidiary":6.0,"bps":1339.51,"equityRatio":0.698,"cashAndCashEquivalents":1813965000.0,"assets":9922918000.0,"currentAssets":5555373000.0,"fixedAsset":4367545000.0,"tangibleFixedAssets":2717176000.0,"intangibleFixedAssets":123231000.0,"investmentAndOtherAssets":1527136000.0,"liabilities":2996538000.0,"currentLiabilities":2068689000.0,"shorTermDept":994996000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":927848000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":856531000.0,"netAsset":6926380000.0,"capitalStock":6880041000.0,"capital":4482936000.0,"capitalSurplus":4198605000.0,"accumulatedEarnings":-1757711000.0,"treasuryStock":-43788000.0,"valuationAndConversionAdjustments":46339000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":7072108000.0,"costOfSales":3066475000.0,"grossProfit":4005632000.0,"sgaExpenses":3884711000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1202060000.0,"operatingIncome":120921000.0,"nonOperatingIncome":52628000.0,"nonOperatingExpenses":161682000.0,"interestExpense":17763000.0,"ordinaryProfit":11867000.0,"extraordinaryGain":11073000.0,"extraordinaryLoss":55027000.0,"incomeBeforeTax":-32086000.0,"incomeTaxes":27351000.0,"netIncome":-59438000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-59438000.0,"comprehensiveIncome":-40155000.0,"eps":-11.49,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":-0.009,"cashFlowFromOperatingActivities":275904000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-651753000.0,"cashFlowFromFinancialActivities":-369604000.0,"changesInCashAndCashEquivalents":-682014000.0,"列1":"asr","submitDate":"2018\/6\/22","stockCode":4557,"accountingYear":"第49期（自　平成29年４月１日　至　平成30年３月31日）","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00978","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4482,"settlementDate":"2022\/3\/31","submitterName":"株式会社医学生物学研究所","submitterNameEnglish":"MEDICAL&BIOLOGICAL LABORATORIES CO., LTD.","submitterNameKana":"カブシキガイシャイガクセイブツガクケンキュウショ","location":"名古屋市中区栄四丁目５番３号","industory":"医薬品","corporateNumber":7180000000000.0},{"edinetCode":"E00978","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":397.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3279000.0,"sharesOwendPercent":0.6341,"outstandingShares":null,"numberOfSubsidiary":5.0,"bps":1390.34,"equityRatio":0.718,"cashAndCashEquivalents":2216608000.0,"assets":10008654000.0,"currentAssets":6450583000.0,"fixedAsset":3558071000.0,"tangibleFixedAssets":2133105000.0,"intangibleFixedAssets":323158000.0,"investmentAndOtherAssets":1101807000.0,"liabilities":2819479000.0,"currentLiabilities":2131664000.0,"shorTermDept":844778000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":687815000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":621757000.0,"netAsset":7189174000.0,"capitalStock":7200600000.0,"capital":4482936000.0,"capitalSurplus":4198605000.0,"accumulatedEarnings":-1437079000.0,"treasuryStock":-43861000.0,"valuationAndConversionAdjustments":-11426000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":8182596000.0,"costOfSales":3665661000.0,"grossProfit":4516934000.0,"sgaExpenses":4028372000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1268571000.0,"operatingIncome":488562000.0,"nonOperatingIncome":90898000.0,"nonOperatingExpenses":27270000.0,"interestExpense":12234000.0,"ordinaryProfit":552190000.0,"extraordinaryGain":128415000.0,"extraordinaryLoss":274512000.0,"incomeBeforeTax":406093000.0,"incomeTaxes":89230000.0,"netIncome":316862000.0,"netIncomeAttributableToOwnersOfTheParentCompany":316862000.0,"comprehensiveIncome":259096000.0,"eps":61.28,"dilutedEps":null,"dividendPerShare":null,"per":31.0,"roe":0.045,"cashFlowFromOperatingActivities":822460000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-5845000.0,"cashFlowFromFinancialActivities":-403288000.0,"changesInCashAndCashEquivalents":405977000.0,"列1":"asr","submitDate":"2019\/6\/26","stockCode":4557,"accountingYear":"第50期（自　2018年４月１日　至　2019年３月31日）","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00978","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4482,"settlementDate":"2022\/3\/31","submitterName":"株式会社医学生物学研究所","submitterNameEnglish":"MEDICAL&BIOLOGICAL LABORATORIES CO., LTD.","submitterNameKana":"カブシキガイシャイガクセイブツガクケンキュウショ","location":"名古屋市中区栄四丁目５番３号","industory":"医薬品","corporateNumber":7180000000000.0},{"edinetCode":"E00978","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.763,"cashAndCashEquivalents":null,"assets":9876135000.0,"currentAssets":6388726000.0,"fixedAsset":3487409000.0,"tangibleFixedAssets":2114749000.0,"intangibleFixedAssets":302758000.0,"investmentAndOtherAssets":1069901000.0,"liabilities":2345474000.0,"currentLiabilities":1760425000.0,"shorTermDept":799768000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":585049000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":526770000.0,"netAsset":7530661000.0,"capitalStock":7529623000.0,"capital":4482936000.0,"capitalSurplus":4198605000.0,"accumulatedEarnings":-1107980000.0,"treasuryStock":-43937000.0,"valuationAndConversionAdjustments":1037000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":2217610000.0,"costOfSales":926354000.0,"grossProfit":1291255000.0,"sgaExpenses":933247000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":358007000.0,"nonOperatingIncome":11180000.0,"nonOperatingExpenses":25578000.0,"interestExpense":2419000.0,"ordinaryProfit":343610000.0,"extraordinaryGain":4512000.0,"extraordinaryLoss":0.0,"incomeBeforeTax":348123000.0,"incomeTaxes":19024000.0,"netIncome":329098000.0,"netIncomeAttributableToOwnersOfTheParentCompany":329098000.0,"comprehensiveIncome":341562000.0,"eps":63.65,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/9","stockCode":4557,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00978","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4482,"settlementDate":"2022\/3\/31","submitterName":"株式会社医学生物学研究所","submitterNameEnglish":"MEDICAL&BIOLOGICAL LABORATORIES CO., LTD.","submitterNameKana":"カブシキガイシャイガクセイブツガクケンキュウショ","location":"名古屋市中区栄四丁目５番３号","industory":"医薬品","corporateNumber":7180000000000.0},{"edinetCode":"E00978","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3209000.0,"sharesOwendPercent":0.6207,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.754,"cashAndCashEquivalents":2628224000.0,"assets":10324175000.0,"currentAssets":6868670000.0,"fixedAsset":3455504000.0,"tangibleFixedAssets":2132216000.0,"intangibleFixedAssets":296946000.0,"investmentAndOtherAssets":1026341000.0,"liabilities":2541526000.0,"currentLiabilities":2045046000.0,"shorTermDept":747905000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":496479000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":435296000.0,"netAsset":7782649000.0,"capitalStock":7780249000.0,"capital":4482936000.0,"capitalSurplus":4198605000.0,"accumulatedEarnings":-857354000.0,"treasuryStock":-43937000.0,"valuationAndConversionAdjustments":2399000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":4539007000.0,"costOfSales":1896115000.0,"grossProfit":2642892000.0,"sgaExpenses":1873090000.0,"salaryAndBenefit":586885000.0,"depreciationAndSGA":null,"RDExpenses":389614000.0,"operatingIncome":769801000.0,"nonOperatingIncome":25695000.0,"nonOperatingExpenses":124409000.0,"interestExpense":4625000.0,"ordinaryProfit":671087000.0,"extraordinaryGain":4512000.0,"extraordinaryLoss":9165000.0,"incomeBeforeTax":666434000.0,"incomeTaxes":86709000.0,"netIncome":579724000.0,"netIncomeAttributableToOwnersOfTheParentCompany":579724000.0,"comprehensiveIncome":593550000.0,"eps":112.12,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":836658000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-119213000.0,"cashFlowFromFinancialActivities":-294874000.0,"changesInCashAndCashEquivalents":411616000.0,"列1":"q2r","submitDate":"2019\/11\/8","stockCode":4557,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00978","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4482,"settlementDate":"2022\/3\/31","submitterName":"株式会社医学生物学研究所","submitterNameEnglish":"MEDICAL&BIOLOGICAL LABORATORIES CO., LTD.","submitterNameKana":"カブシキガイシャイガクセイブツガクケンキュウショ","location":"名古屋市中区栄四丁目５番３号","industory":"医薬品","corporateNumber":7180000000000.0},{"edinetCode":"E00978","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.772,"cashAndCashEquivalents":null,"assets":10529406000.0,"currentAssets":7080479000.0,"fixedAsset":3448926000.0,"tangibleFixedAssets":2156784000.0,"intangibleFixedAssets":289720000.0,"investmentAndOtherAssets":1002420000.0,"liabilities":2404402000.0,"currentLiabilities":1983848000.0,"shorTermDept":693096000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":420554000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":365318000.0,"netAsset":8125003000.0,"capitalStock":8137776000.0,"capital":4482936000.0,"capitalSurplus":4198605000.0,"accumulatedEarnings":-499827000.0,"treasuryStock":-43937000.0,"valuationAndConversionAdjustments":-12773000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":6851179000.0,"costOfSales":2776890000.0,"grossProfit":4074288000.0,"sgaExpenses":2907544000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":1166743000.0,"nonOperatingIncome":32108000.0,"nonOperatingExpenses":105266000.0,"interestExpense":6518000.0,"ordinaryProfit":1093586000.0,"extraordinaryGain":4512000.0,"extraordinaryLoss":17530000.0,"incomeBeforeTax":1080569000.0,"incomeTaxes":143317000.0,"netIncome":937251000.0,"netIncomeAttributableToOwnersOfTheParentCompany":937251000.0,"comprehensiveIncome":935904000.0,"eps":181.26,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/13","stockCode":4557,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00978","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4482,"settlementDate":"2022\/3\/31","submitterName":"株式会社医学生物学研究所","submitterNameEnglish":"MEDICAL&BIOLOGICAL LABORATORIES CO., LTD.","submitterNameKana":"カブシキガイシャイガクセイブツガクケンキュウショ","location":"名古屋市中区栄四丁目５番３号","industory":"医薬品","corporateNumber":7180000000000.0},{"edinetCode":"E00978","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":408.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3221000.0,"sharesOwendPercent":0.6231,"outstandingShares":null,"numberOfSubsidiary":5.0,"bps":1635.03,"equityRatio":0.737,"cashAndCashEquivalents":3500707000.0,"assets":11478337000.0,"currentAssets":7822118000.0,"fixedAsset":3656219000.0,"tangibleFixedAssets":2112276000.0,"intangibleFixedAssets":288786000.0,"investmentAndOtherAssets":1255155000.0,"liabilities":3024009000.0,"currentLiabilities":2653723000.0,"shorTermDept":651417000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":370286000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":310340000.0,"netAsset":8454327000.0,"capitalStock":8467351000.0,"capital":4482936000.0,"capitalSurplus":4198605000.0,"accumulatedEarnings":-170098000.0,"treasuryStock":-44090000.0,"valuationAndConversionAdjustments":-13023000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":9229857000.0,"costOfSales":3824639000.0,"grossProfit":5405218000.0,"sgaExpenses":4070716000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":954640000.0,"operatingIncome":1334502000.0,"nonOperatingIncome":42969000.0,"nonOperatingExpenses":50876000.0,"interestExpense":8311000.0,"ordinaryProfit":1326594000.0,"extraordinaryGain":7504000.0,"extraordinaryLoss":173382000.0,"incomeBeforeTax":1160716000.0,"incomeTaxes":-106264000.0,"netIncome":1266980000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1266980000.0,"comprehensiveIncome":1265382000.0,"eps":245.03,"dilutedEps":null,"dividendPerShare":null,"per":15.1,"roe":0.162,"cashFlowFromOperatingActivities":2121111000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-298953000.0,"cashFlowFromFinancialActivities":-528228000.0,"changesInCashAndCashEquivalents":1284099000.0,"列1":"asr","submitDate":"2020\/6\/24","stockCode":4557,"accountingYear":"第51期（自　2019年４月１日　至　2020年３月31日）","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00978","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4482,"settlementDate":"2022\/3\/31","submitterName":"株式会社医学生物学研究所","submitterNameEnglish":"MEDICAL&BIOLOGICAL LABORATORIES CO., LTD.","submitterNameKana":"カブシキガイシャイガクセイブツガクケンキュウショ","location":"名古屋市中区栄四丁目５番３号","industory":"医薬品","corporateNumber":7180000000000.0},{"edinetCode":"E00978","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.768,"cashAndCashEquivalents":null,"assets":11361957000.0,"currentAssets":7702408000.0,"fixedAsset":3659548000.0,"tangibleFixedAssets":2152078000.0,"intangibleFixedAssets":271966000.0,"investmentAndOtherAssets":1235504000.0,"liabilities":2633064000.0,"currentLiabilities":2304252000.0,"shorTermDept":611408000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":328812000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":255362000.0,"netAsset":8728892000.0,"capitalStock":8756102000.0,"capital":4482936000.0,"capitalSurplus":4198605000.0,"accumulatedEarnings":118651000.0,"treasuryStock":-44090000.0,"valuationAndConversionAdjustments":-27209000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":2191858000.0,"costOfSales":832644000.0,"grossProfit":1359213000.0,"sgaExpenses":1012737000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":346476000.0,"nonOperatingIncome":9436000.0,"nonOperatingExpenses":9669000.0,"interestExpense":1972000.0,"ordinaryProfit":346243000.0,"extraordinaryGain":40000.0,"extraordinaryLoss":168000.0,"incomeBeforeTax":346116000.0,"incomeTaxes":57365000.0,"netIncome":288750000.0,"netIncomeAttributableToOwnersOfTheParentCompany":288750000.0,"comprehensiveIncome":274564000.0,"eps":55.84,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/6","stockCode":4557,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00978","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4482,"settlementDate":"2022\/3\/31","submitterName":"株式会社医学生物学研究所","submitterNameEnglish":"MEDICAL&BIOLOGICAL LABORATORIES CO., LTD.","submitterNameKana":"カブシキガイシャイガクセイブツガクケンキュウショ","location":"名古屋市中区栄四丁目５番３号","industory":"医薬品","corporateNumber":7180000000000.0},{"edinetCode":"E00978","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3138000.0,"sharesOwendPercent":0.607,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.8,"cashAndCashEquivalents":3328329000.0,"assets":11655447000.0,"currentAssets":8092676000.0,"fixedAsset":3562771000.0,"tangibleFixedAssets":2159335000.0,"intangibleFixedAssets":256938000.0,"investmentAndOtherAssets":1146497000.0,"liabilities":2336537000.0,"currentLiabilities":2075106000.0,"shorTermDept":574912000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":261431000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":200384000.0,"netAsset":9318909000.0,"capitalStock":9352257000.0,"capital":4482936000.0,"capitalSurplus":4198605000.0,"accumulatedEarnings":714807000.0,"treasuryStock":-44090000.0,"valuationAndConversionAdjustments":-33347000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":4967815000.0,"costOfSales":1866042000.0,"grossProfit":3101772000.0,"sgaExpenses":2008837000.0,"salaryAndBenefit":622648000.0,"depreciationAndSGA":null,"RDExpenses":531987000.0,"operatingIncome":1092934000.0,"nonOperatingIncome":17279000.0,"nonOperatingExpenses":30875000.0,"interestExpense":3613000.0,"ordinaryProfit":1079339000.0,"extraordinaryGain":40000.0,"extraordinaryLoss":14271000.0,"incomeBeforeTax":1065107000.0,"incomeTaxes":180201000.0,"netIncome":884906000.0,"netIncomeAttributableToOwnersOfTheParentCompany":884906000.0,"comprehensiveIncome":864582000.0,"eps":171.14,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":164754000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-113911000.0,"cashFlowFromFinancialActivities":-202362000.0,"changesInCashAndCashEquivalents":-172377000.0,"列1":"q2r","submitDate":"2020\/11\/12","stockCode":4557,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00978","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":4482,"settlementDate":"2022\/3\/31","submitterName":"株式会社医学生物学研究所","submitterNameEnglish":"MEDICAL&BIOLOGICAL LABORATORIES CO., LTD.","submitterNameKana":"カブシキガイシャイガクセイブツガクケンキュウショ","location":"名古屋市中区栄四丁目５番３号","industory":"医薬品","corporateNumber":7180000000000.0}]